



Eric Kaldjian¹, Nick Drovetto¹, Daniel Campton¹, Arturo Ramirez¹, Jackie Stilwell¹, Alisa Clein², Daniel Sabath², Ruth Dumpit³, Pete Nelson³.

¹RareCyte, Inc., ²University of Washington, Laboratory Medicine, ³Fred Hutchinson Cancer Research Center, Seattle, WA

EK, ND, DC, AR, JS are employees of RareCyte. PN and RD receive funding from PCF and FHCRC STTR grants.

Background

Analysis of circulating tumor cells (CTC) allows non-invasive investigation of cancer biology and response to treatment at several levels. The primary level is the CTC count, which has been demonstrated to be prognostic of outcome in multiple cancer types. Characterization of CTC phenotype and pertinent biomarkers, including drug targets, is a second level. Single cell molecular/genomic analysis of CTCs provides a third level. RareCyte has developed AccuCyte® – CyteFinder® (AC-CF), an integrated technology platform for highly sensitive visual identification and retrieval of rare cells in blood. The AccuCyte kit comprehensively collects the nucleated cell fraction of the blood and transfers it to a microscope slide compatible with automated immunostaining and other slide-based tissue tests. CyteFinder is a highly precise digital scanning fluorescence microscope with image analysis software for multi-parameter visual characterization and integrated mechanical isolation of single cells for genomic analysis.


Methods

Model CTC (mCTC) prostate cancer lines were used to assess capture efficiency and limit of detection. Blood samples from University of Washington (UW) patients with advanced prostate cancer were used to compare blinded CTC counts with the FDA-cleared CellSearch® system using 4-channel immunofluorescence. An additional set of 45 samples from 30 advanced prostate cancer patients from UW patients were analyzed using AC-CF at RareCyte's laboratory. Prototypic 6-channel prostate cancer marker-specific panels were developed. Individual prostate CTCs were retrieved from slides.

Results

Capture efficiency of mCTCs was over 90%, with limit of detection of 1 cell in 7.5 mL. Enumeration performance of AC-CF matched or exceeded that of CellSearch, depending on levels of EpCAM expression in mCTC cell lines, with higher expressing lines closely matching CellSearch counts and lower expressing lines exceeding CellSearch counts. Of the 30-patients, 9 had no CTCs, 7 had 1 – 3, 3 had 4 – 9, and 11 had 10 or more CTCs. Large CTC clusters were identified in two samples. A 6-channel IF assay using SYTOX-Orange (DNA stain), cytokeratin, EpCAM, androgen receptor (AR), PSMA and CD45 was successfully applied to mCTC and clinical samples. An assay for AR variant 7 (ARv7) identified mCTCs known to express the ARv7 splice variant. AR and PSMA were expressed in the majority of epithelial-marker positive CTCs. Individual CTCs were retrieved after on-slide visual identification and re-visualized after placement in flat-bottom PCR tubes for confirmation.

High recovery of model CTCs from whole blood



- Individually counted cells (range ~70 – 200) were spiked into 7.5 mL whole blood.
- Samples were processed using AC – CF .
- Mean recovery of **more than 90%** across various cell lines using different automated staining systems.

Single-digit spike-in recovery of model CTCs


Test	1	2	3	4	5	6	7	8	9	10	11	12
Spike-in Cells	2	1	0	2	0	1	5	3	3	3	6	1
Identified Cells	2	1	0	2	0	0	4	2	3	3	4	1

- Individual PC3 cells were isolated using CytePicker and spiked into 7.5 mL whole blood.
- Recovery of more than 80% of single-digit spike-in PC3 cells.
- Limit of detection of **1 cell** in 7.5 mL whole blood.


Conclusions

AccuCyte – CyteFinder is a highly sensitive, comprehensive technology for the identification of CTCs. AC-CF identifies equivalent or greater numbers of CTCs in advanced prostate cancer patients than CellSearch. The majority of advanced prostate cancer patients evaluated had identifiable CTCs. 6-parameter multiplex phenotyping of prostate cancer CTCs is feasible and individually identified cells can be isolated for molecular analysis. Additional studies in bone marrow have been designed to confirm that CD45 (-), cytokeratin (+), EpCAM (+) cells are bone fide tumor cells distinct from resident marrow cells.

Platform comparison to CellSearch



II. Clinical prostate cancer samples




- AC-CF CTC count matches or exceeds CellSearch count in CTC models and in prostate cancer patient samples.

CTC counts in 30-patient prostate cancer cohort

CTC count	0	1 - 3	4 - 9	10+	Large cell clusters (50+)
Patients (N=30)	9	7	3	11	2
Fraction	30%	23%	10%	37%	7%


Low EpCAM mCTCs found by AC – CF




PC3 model CTCs with high (arrowheads) and low (arrows) EpCAM expression.

Prostate cancer biomarker panels


A. 6-channel panel (LNCaP cells) B. AR v7 (22RV1 cells)



C. 6-channel panel (patient CTC cluster) Composite image



Integrated individual cell retrieval



Laboratory Workflow

- Density enrichment
- Automated staining
- Image analysis

